Risk of senescence, polypharmacy, and their outcomes in elderly cardiovascular disease patients

Area of Science:

• Gerontology
• Cardiology
• Pharmacology

Background:

• Cardiovascular diseases (CVDs) are linked to senescence and age-related comorbidities.
• Elderly patients with CVDs often have multiple morbidities and polypharmacotherapy, increasing risks.
• Polypharmacy, routine cardiovascular drugs, and altered pharmacokinetics pose significant challenges in cardiovascular practice.

Purpose of the Study:

• To examine the cardiometabolic effects of polypharmacy in elderly patients with CVDs.
• To propose optimal senotherapeutic and drug management strategies for cardiac surgery in this population.

Main Methods:

• Review of existing literature on polypharmacy, senescence, and CVDs in the elderly.
• Analysis of challenges in drug management and senotherapeutic interventions.
• Development of strategic approaches for managing elderly cardiac surgical patients.

Main Results:

• Polypharmacy in elderly CVD patients increases the risk of drug interactions and adverse drug reactions (ADRs).
• Age-related pharmacokinetic changes exacerbate medication management difficulties.
• Senescence and multiple comorbidities complicate treatment efficacy and patient recovery.

Conclusions:

• Managing polypharmacy in elderly CVD patients requires careful consideration of drug interactions and safety.
• Optimized senotherapeutic and drug management strategies are crucial for improving outcomes in cardiac surgery.
• Addressing the complexities of aging, morbidity, and polypharmacy is essential for effective cardiovascular care.